Waverley Pharma Inc. (TSXV:WAVE)
Canada · Delayed Price · Currency is CAD 0.0150
0.00 (0.00%)
At close: Aug 19, 2026
Waverley Pharma Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1.25 | 1.35 | 0.48 | 0.41 | 1.25 | 1.75 | |
Revenue Growth | 43.69% | 183.90% | 15.36% | -66.95% | -28.87% | 27.47% |
Cost of Revenue | 0.78 | 0.84 | 0.26 | 0.33 | 0.96 | 1.53 |
Gross Profit | 0.46 | 0.51 | 0.21 | 0.08 | 0.28 | 0.22 |
Selling, General & Admin | 0.9 | 0.85 | 0.65 | 1.13 | 1.14 | 0.98 |
Research & Development | 0.01 | 0.01 | 0.42 | 0.23 | 0.08 | 0.03 |
Operating Expenses | 0.92 | 0.86 | 1.08 | 1.36 | 1.22 | 1.01 |
Operating Income | -0.45 | -0.35 | -0.86 | -1.28 | -0.94 | -0.79 |
Interest Expense | -0.18 | -0.18 | -0.16 | -0.08 | -0.02 | -0 |
Interest & Investment Income | 0 | 0 | 0 | 0 | - | - |
Currency Exchange Gain (Loss) | 0 | 0.03 | -0.04 | -0 | -0.01 | -0.05 |
Other Non Operating Income (Expenses) | -0 | -0 | 0.12 | 0.08 | 0.3 | 0.04 |
EBT Excluding Unusual Items | -0.63 | -0.5 | -0.95 | -1.28 | -0.66 | -0.8 |
Asset Writedown | - | - | - | -0.94 | - | - |
Pretax Income | -0.63 | -0.5 | -0.95 | -2.22 | -0.66 | -0.8 |
Income Tax Expense | 0 | 0 | - | - | - | - |
Net Income | -0.63 | -0.5 | -0.95 | -2.22 | -0.66 | -0.8 |
Net Income to Common | -0.63 | -0.5 | -0.95 | -2.22 | -0.66 | -0.8 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 54 | 54 | 54 | 54 | 54 | 54 |
Shares Outstanding (Diluted) | 54 | 54 | 54 | 54 | 54 | 54 |
Shares Change | - | - | - | - | - | - |
EPS (Basic) | -0.01 | -0.01 | -0.02 | -0.04 | -0.01 | -0.01 |
EPS (Diluted) | -0.01 | -0.01 | -0.02 | -0.04 | -0.01 | -0.01 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 37.34% | 38.06% | 45.03% | 19.36% | 22.76% | 12.70% |
Operating Margin | -36.34% | -25.89% | -181.32% | -311.30% | -75.08% | -44.89% |
Profit Margin | -50.47% | -36.99% | -199.23% | -539.70% | -53.26% | -45.44% |
EBITDA | -0.4 | -0.29 | -0.85 | -0.96 | -0.83 | -0.76 |
EBITDA Margin | -31.77% | -21.60% | -177.78% | -233.19% | -66.44% | -43.28% |
D&A For EBITDA | 0.06 | 0.06 | 0.02 | 0.32 | 0.11 | 0.03 |
EBIT | -0.45 | -0.35 | -0.86 | -1.28 | -0.94 | -0.79 |
EBIT Margin | -36.34% | -25.89% | -181.32% | - | -75.08% | -44.89% |